{"generic":"Taliglucerase Alfa","drugs":["Elelyso","Taliglucerase Alfa"],"mono":{"0":{"id":"930203-s-0","title":"Generic Names","mono":"Taliglucerase Alfa"},"1":{"id":"930203-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930203-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Gaucher's disease, Type 1:<\/b> treatment-naive, 60 units\/kg IV over 60 to 120 minutes every 2 weeks; adjust dose based on therapeutic goals<\/li><li><b>Gaucher's disease, Type 1:<\/b> switching from imiglucerase therapy, use the same unit\/kg dose in stable patients; adjust dose based on therapeutic goals<\/li><\/ul>"},"1":{"id":"930203-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Gaucher's disease, Type 1:<\/b> (4 years or older) treatment-naive, 60 units\/kg IV over 60 to 120 minutes every 2 weeks; adjust dose based on therapeutic goals<\/li><li><b>Gaucher's disease, Type 1:<\/b> (4 years or older) switching from imiglucerase therapy, use the same unit\/kg dose in stable patients; adjust dose based on therapeutic goals<\/li><\/ul>"},"3":{"id":"930203-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Gaucher's disease, Type 1<br\/>"}}},"3":{"id":"930203-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930203-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930203-s-3-10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- serious hypersensitivity reactions including anaphylaxis have been reported during taliglucerase infusion; discontinue treatment immediately and rechallenge with caution<\/li><li>-- hypersensitivity reactions have been reported; slowing or interruption of the infusion may be necessary<\/li><\/ul>"},{"id":"930203-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"930203-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930203-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea (9%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (13%), Pain in limb (10%)<\/li><li><b>Neurologic:<\/b>Dizziness (9%), Headache (13% to 19%)<\/li><li><b>Other:<\/b>Fatigue (9%)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis (2.8%)<br\/>"},"6":{"id":"930203-s-6","title":"Drug Name Info","sub":{"0":{"id":"930203-s-6-17","title":"US Trade Names","mono":"Elelyso<br\/>"},"2":{"id":"930203-s-6-19","title":"Class","mono":"<ul><li>Enzyme<\/li><li>Enzyme Replacement<\/li><\/ul>"},"3":{"id":"930203-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930203-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930203-s-7","title":"Mechanism Of Action","mono":"Taliglucerase alfa, a hydrolytic lysosomal glucocerebroside-specific enzyme, catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. In patients with type 1 Gaucher disease, treatment with taliglucerase alfa reduced spleen and liver size, and stabilized hematologic parameters.<br\/>"},"8":{"id":"930203-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"930203-s-8-24","title":"Distribution","mono":"Vd: 8.8 to 14.9 L <br\/>"},"3":{"id":"930203-s-8-26","title":"Excretion","mono":"Total body clearance: 15.8 to 30.5 L\/hr <br\/>"},"4":{"id":"930203-s-8-27","title":"Elimination Half Life","mono":"18.9 to 37.1 minutes <br\/>"}}},"9":{"id":"930203-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>calculate the necessary dose and number of vials, rounding up to the next whole vial; remove the required number of vials from the refrigerator; do not leave vials out of refrigerator longer than 24 hours prior to reconstitution.<\/li><li>reconstitute each vial with 5.1 mL sterile water for injection; mix gently; do not shake; withdrawal volume is 5 mL<\/li><li>withdraw calculated dose and dilute in NS to a final volume 100 to 120 mL for pediatric patients and 130 to 150 mL for adult patients; final volume should be a maximum of 200 mL for adults using more than 130 to 150 mL of reconstituted product; mix gently and do not shake<\/li><li>slight flocculation may occur in diluted solution, but solution is still acceptable for administration<\/li><li>reconstituted solution is stable for 24 hours when stored under refrigeration at 2 to 8 degrees C (36 to 46 degrees F) and protected from light; it may also be stored at room temperature (20 to 25 degrees C or 68 to 77 degrees F) and without protection from light for up to 4 hours<\/li><li>diluted solution is stable for 24 hours when stored under refrigeration at 2 to 8 degrees C (36 to 46 degrees F) and protected from light<\/li><li>(pediatric patients) infuse IV over at least 1 hour through a 0.2 micrometer inline low protein-binding filter; initial infusion rate is 1 mL\/min and may be increased to 2 mL\/min as tolerated<\/li><li>(adult patients) infuse IV over at least 1 hour through a 0.2 micrometer inline low protein-binding filter; initial infusion rate is 1.2 mL\/min and may be increased to 2.2 mL\/min as tolerated<\/li><\/ul>"},"10":{"id":"930203-s-10","title":"Monitoring","mono":"<ul><li>improvement in signs\/symptoms of Type 1 Gaucher disease indicates efficacy<\/li><li>IgG antidrug antibody formation; in patients with immune or infusion reactions<\/li><\/ul>"},"11":{"id":"930203-s-11","title":"How Supplied","mono":"<b>Elelyso<\/b><br\/>Intravenous Powder for Solution: 200 U<br\/>"},"13":{"id":"930203-s-13","title":"Clinical Teaching","mono":"Drug may cause headache, fatigue, urticaria, pain in the joints, back, or limbs, pharyngitis, and influenza. <br\/>"}}}